Tags : Stanford Medicine

PharmaShots Weekly Snapshot (November 11-15, 2019)

Roche’s Kadcyla (trastuzumab emtansine) Receives CHMP’s Recommendation for Approval as an Adjuvant Treatment for Patients with HER2+ eBC with Residual Invasive Disease After Neoadjuvant Treatment Published: Nov 15, 2019 | Tags: Roche, Kadcyla, trastuzumab emtansine, Receives, CHMP, Recommendation, Approval, Adjuvant, Treatment, HER2+ Early Breast Cancer 2. Stanford Medicine Reports Results of Apple Heart Study for Detecting […]Read More

Stanford Medicine Reports Results of Apple Heart Study for Detecting

Shots: The Apple Heart Study was started in Nov’2017 in conjunction with the release of Apple’s fourth-generation smartwatch and watchOS 4. The study evaluated 419,297 participants and demonstrated that 0.5% of them received irregular heart rhythm notifications, published in NEJM Those who were flagged for an irregular pulse received follow-up care via the ECG patch. […]Read More